The California biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag in combination with tirzepatide ...

A Johns Hopkins surgeon, Marty Makary also serves as a board member or adviser to several companies, including one that ...

The two partners disclosed study results supporting an approval application for their drug dato-dxd. Elsewhere, Agenus cut ...

The expansion of a newly acquired facility in Wisconsin is Lilly’s largest U.S. manufacturing investment outside of Indiana ...

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...

The venture firm’s “modest” $450 million fund, a lower total than some of its peers recently raised, reflects lessons learned ...

The company is developing treatments to rebalance, rather than suppress, immune function in people with inflammatory ...

The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a ...

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier ...